Mead Johnson Eyes China’s One-Child Policy, Hong Kong Formula Rule
This article was originally published in The Tan Sheet
The one-child policy in much of China stifles Mead Johnson’s annual formula volume growth there, says incoming CEO Kasper Jakobsen. Formula sales there could be slowed with Hong Kong limiting the amount that consumers can take out of the territory.
You may also be interested in...
Jakobsen next in line as Mead Johnson CEO; Blake takes over Bayer U.S. from Babe; Himmel ends brief tenure as ChromaDex CEO; Capitol Hill veteran O’Donnell joins NACDS; Merz makes Hartman derma VP; USANA strengthens scientist roster; more People In Brief.
Nestle’s $11.85 billion acquisition of Pfizer’s pediatric nutritionals business came in above or at the upper end of most analysts’ expectations. With the deal, Nestle keeps the portfolio – projected to generate $2.4 billion in 2012 sales – away from rivals Danone and Mead Johnson.
Five firms' “representations create a false impression that [their] products have been authorized for emergency use by FDA and are misleading," states FDA's medical device center.